Ignite Proteomics LLC collaborates with Inova Health to use RPPA technology on tumor samples from late-stage gastrointestinal cancer patients. Up to 600 samples will be analyzed to generate biomarker data for treatment decision-making. The partnership aims to accelerate precision medicine for gastrointestinal cancers. This collaboration represents a significant research service for Ignite Proteomics and is expected to boost the company’s revenue in 2025. Ignite Proteomics delivers pathway-level protein analytics to guide precision oncology, matching patients with effective therapies through their CLIA-certified lab. The collaboration with Inova is focused on bringing advanced science into clinical practice for late-stage cancer patients.

Read more at GlobeNewswire: Ignite Proteomics Announces Collaboration with Inova Health